The system is designed to standardize pre-analytical workflows and reduce inconsistency in molecular testing.
Invivoscribe announced the launch of the PrepQuant System, a sample preparation platform that integrates nucleic acid extraction, concentration, and quantification into a single automated instrument.
Developed in collaboration with Hitachi High-Tech Corporation, the system is intended to standardize sample preparation and simplify pre-analytical workflows to reduce laboratory costs and eliminate a primary source of inconsistency in molecular testing. The platform combines Invivoscribe’s experience in molecular assays and clinical testing services with Hitachi High-Tech’s manufacturing capabilities.
The platform is assay agnostic and generates genomic DNA and cell-free DNA yields for next-generation sequencing, quantitative polymerase chain reaction, and digital PCR assays. By consolidating multiple steps into one platform, the system is designed to reduce operating costs, sample variability, and lab bench space.
“The PrepQuant System represents a significant advancement in our commitment to standardize the entire testing process, starting with the pre-analytical workflow,” says Jeff Miller, CEO and chief scientific officer of Invivoscribe, in a release. “By integrating extraction, concentration, and quantification in one platform, we reduce variability to help ensure generation of consistent, high-quality test results. This is particularly important in the era of precision medicine, where reliability of MRD and liquid biopsy results depend markedly on the quality and consistency of the starting material.”
The system was developed based on insights from LabPMM, the company’s global network of testing laboratories, which identified limitations in current automated instruments.
“Our teams recognized the limitations of currently available automated instruments, particularly the labor-intensive nature and increased risk of errors associated with running three separate protocols across multiple instruments,” says Jordan Thornes, vice president of global clinical laboratory operations, in a release. “This all-in-one system was designed to reduce costs, while addressing those challenges and significantly improving operational efficiency.”
The system is validated for use with blood, plasma, and bone marrow specimens, and development is ongoing for additional specimen types.
Invivoscribe displayed the platform at the American Association for Cancer Research Annual Meeting in San Diego from April 19 to 22. The company is currently issuing quotes and expects the first commercial shipments in North America to begin in August 2026, with European availability scheduled for January 2027. New kit releases are planned by the end of 2026 to expand the system’s menu and versatility.
